PRODUCT INFORMATION

BMS 753

Item No. 29493

CAS Registry No.:	215307-86-1
Formal Name:	4-[[(2,3-dihydro-1,1,3,3-tetramethyl-2-oxo-1H-inden-5-yl) carbonyl]amino]-benzoic acid
MF:	$C_{21}H_{21}NO_4$
FW:	351.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 289 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BMS 753 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMS 753 in the solvent of choice, which should be purged with an inert gas. BMS 753 is soluble in organic solvents such as ethanol and DMSO.

Description

BMS 753 is a synthetic retinoid and retinoic acid receptor α (RARα) agonist (K_i = 2 nM).[1] It is selective for RARα over RARγ at 1 µM. BMS 753 (10 and 100 nM) induces morphological differentiation of P19 embryonal carcinoma cells, as well as F9 embryonal carcinoma cells when used at a concentration of 100 nM in combination with the pan-retinoid X receptor (RXR) agonist BMS649.[2]

References

1. Géhin, M., Vivat, V., Wurtz, J.M., *et al.* Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. *Chem. Biol.* **6(8),** 519-529 (1999).
2. Taneja, R., Roy, B., Plassat, J.L., *et al.* Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RARβ2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. *Proc. Natl. Acad. Sci. USA* **93(12),** 6197-6202 (1996).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM